Sevelamer Carbonate Tablets 400 MG
SIMER – 400 mg
Sevelamer is used to lower high blood phosphorus (phosphate) levels in patients who are on dialysis due to severe kidney disease. Dialysis removes some phosphate from your blood, but it is difficult to remove enough to keep your phosphate levels balanced. Decreasing blood phosphate levels can help keep your bones strong, prevent unsafe buildup of minerals in your body, and possibly decrease the risk of heart disease and strokes that can result from high phosphate levels. Sevelamer works by holding onto phosphate from the diet so that it can pass out of your body.
Sevelamer is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer consists of polyallylamine that is crosslinked with epichlorohydrin.
Sevelamer is used in the management of hyperphosphatemia in adult patients with stage 4 and 5 chronic kidney disease on hemodialysis. Its efficacy at lowering phosphate levels is similar to that of calcium acetate, but without the accompanying risk of hypercalcemia.
The active ingredient in SIMER is sevelamer carbonate, a polymeric amine that binds phosphate and is meant for oral administration. Sevelamer carbonate is an anion exchange resin, with the same polymeric structure as sevelamer hydrochloride, in which carbonate replaces chloride as the counter ion. While the counter ions differ for the two salts, the polymer itself, the active moiety involved in phosphate binding, is the same.
Sevelamer carbonate is known chemically as poly(allylamine-co-N,N’-diallyl-1,3 diamino-2- hydroxypropane) carbonate salt. Sevelamer carbonate is hygroscopic, but insoluble in water.
Patients with CKD retain phosphorus and can develop Hyperphosphatemia. When the product of serum calcium and phosphorus concentrations (Ca*P) surpasses 55 mg/dL, there is an increased risk that ectopic calcification will occur. Hyperphosphatemia plays a role in the development of secondary hyperparathyroidism in renal insufficiency.
Management of Hyperphosphatemia includes Diet, Dialysis and use of Phosphate Binders. Sevelamer carbonate taken with meals has been shown to control serum phosphorus concentrations in patients with CKD who are on dialysis.
Indication
SIMER (Sevelamer Carbonate 400/800 mg) is a phosphate binder indicated in Hyperphosphatemia for the control of serum phosphorus in patients with Chronic Kidney Disease on dialysis.
Composition
| Sevelamer | 400 mg |
| Excipients | q.s. |
| Colour | Titanium Dioxide I.P. |
Dosage
As directed by physician
Storage
Keep in a dry place at a temperature, not exceeding 30 Degree Celsius. Protect from light.